Advertisement
Canada markets closed

  • S&P/TSX

    21,823.22
    +94.67 (+0.44%)
     

  • S&P 500

    5,064.20
    +45.81 (+0.91%)
     

  • DOW

    38,225.66
    +322.37 (+0.85%)
     

  • CAD/USD

    0.7315
    +0.0034 (+0.47%)
     

  • CRUDE OIL

    79.15
    +0.20 (+0.25%)
     

  • Bitcoin CAD

    81,213.76
    +1,950.32 (+2.46%)
     

  • CMC Crypto 200

    1,275.65
    +4.91 (+0.39%)
     

  • GOLD FUTURES

    2,313.30
    +3.70 (+0.16%)
     

  • RUSSELL 2000

    2,016.11
    +35.88 (+1.81%)
     

  • 10-Yr Bond

    4.5710
    -0.0240 (-0.52%)
     

  • NASDAQ futures

    17,746.00
    +96.25 (+0.55%)
     

  • VOLATILITY

    14.68
    -0.71 (-4.61%)
     

  • FTSE

    8,172.15
    +50.91 (+0.63%)
     

  • NIKKEI 225

    38,236.07
    -37.98 (-0.10%)
     

  • CAD/EUR

    0.6816
    +0.0023 (+0.34%)
     

Stocks in play: Resverlogix Corp.

Baystreet.ca

Today announced the publication of a peer-reviewed article, entitled "Apabetalone, a Clinical-stage, Selective BET Inhibitor, Opposes DUX4 Target Gene Expression in Primary Human FSHD Muscle Cells" in the journal Biomedicines. Resverlogix Corp. shares T.RVX are trading unchanged at $0.07.

Read: